Your browser is no longer supported. Please, upgrade your browser.
Settings
VRTX Vertex Pharmaceuticals Incorporated daily Stock Chart
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E76.30 EPS (ttm)2.50 Insider Own0.10% Shs Outstand254.91M Perf Week2.41%
Market Cap48.56B Forward P/E46.12 EPS next Y4.13 Insider Trans-27.84% Shs Float254.59M Perf Month14.65%
Income646.80M PEG1.34 EPS next Q1.06 Inst Own97.40% Short Float1.56% Perf Quarter2.73%
Sales2.83B P/S17.17 EPS this Y327.00% Inst Trans0.19% Short Ratio2.47 Perf Half Y5.18%
Book/sh11.40 P/B16.71 EPS next Y7.58% ROA18.40% Target Price198.64 Perf Year21.36%
Cash/sh11.99 P/C15.89 EPS next 5Y56.86% ROE30.20% 52W Range144.07 - 194.92 Perf YTD14.97%
Dividend- P/FCF41.19 EPS past 5Y47.60% ROI8.80% 52W High-0.73% Beta1.66
Dividend %- Quick Ratio3.60 Sales past 5Y10.30% Gross Margin86.90% 52W Low34.31% ATR5.84
Employees2300 Current Ratio3.70 Sales Q/Q35.70% Oper. Margin22.50% RSI (14)70.68 Volatility2.53% 3.57%
OptionableYes Debt/Eq0.20 EPS Q/Q220.50% Profit Margin26.70% Rel Volume1.04 Prev Close190.52
ShortableYes LT Debt/Eq0.20 EarningsJan 30 AMC Payout0.00% Avg Volume1.60M Price193.50
Recom1.80 SMA2012.57% SMA5012.44% SMA20014.16% Volume1,258,608 Change1.56%
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Oct-26-18Upgrade H.C. Wainwright Neutral → Buy $220
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Aug-07-18Reiterated Stifel Buy $182 → $200
Mar-05-18Reiterated Maxim Group Buy $195 → $200
Feb-13-18Reiterated JMP Securities Mkt Outperform $200 → $211
Feb-01-18Reiterated Barclays Overweight $180 → $200
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Oct-18-17Reiterated RBC Capital Mkts Outperform $175 → $181
Sep-29-17Initiated BTIG Research Buy $200
Sep-15-17Initiated RBC Capital Mkts Outperform $175
Jul-19-17Upgrade Raymond James Mkt Perform → Outperform
Jul-19-17Upgrade Janney Neutral → Buy
Jul-19-17Upgrade Barclays Equal Weight → Overweight $115 → $180
Jul-19-17Reiterated Stifel Buy $154 → $182
Jul-18-17Reiterated Stifel Buy $130 → $154
Jul-11-17Initiated Jefferies Buy
Jun-23-17Upgrade Needham Hold → Buy $155
Jun-02-17Upgrade Oppenheimer Perform → Outperform
Mar-31-17Upgrade Maxim Group Hold → Buy $143
Jan-12-19 12:00PM  Where Will CRISPR Therapeutics Be in 10 Years? Motley Fool
07:31AM  3 Biotech Stocks to Watch in 2019 Motley Fool
Jan-11-19 04:18PM  Stocks Pare Losses As Small Caps Lead; Why Netflix Led The IBD 50 Investor's Business Daily
04:14PM  Why This IBD Stock Of The Day Broke Out Despite Biotech Turbulence Investor's Business Daily
12:08PM  Vertex Pharmaceuticals Begins Forming A Base Investor's Business Daily Video
Jan-09-19 10:04AM  Moderna (MRNA) Announces Pipeline Progress, Shares Rise Zacks
Jan-08-19 10:12AM  Is Vertex Pharmaceuticals Incorporateds (NASDAQ:VRTX) CEO Being Overpaid? Simply Wall St.
07:15AM  5 Things to Expect for Vertex Pharmaceuticals in 2019 Motley Fool
Jan-07-19 10:03AM  Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag Zacks
Jan-06-19 09:32AM  Outlook For Battered Biotech Stocks In 2019 Investopedia
09:09AM  Better Buy: CRISPR Therapeutics vs. Vertex Pharmaceuticals Motley Fool
Jan-04-19 04:24PM  These Stocks Pop After FDA Expedites Review Of Gene-Editing Therapy Investor's Business Daily +5.48%
10:01AM  Vertex Joins Forces With Arbor to Build Gene-Editing Therapies Zacks
07:00AM  CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease GlobeNewswire
Jan-03-19 10:33AM  Vertex teams up with Feng Zhang startup on gene editing tech American City Business Journals
08:00AM  Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies Business Wire
Jan-02-19 04:27PM  Could This New Biotech IPO Could Score Big With A Cancer Vaccine? Investor's Business Daily
04:01PM  Vertex to Present at the J.P. Morgan Healthcare Conference on January 7 Business Wire
Dec-26-18 02:22PM  6 Valuable Pipeline Drugs With Upcoming Catalysts Benzinga +6.54%
11:50AM  HC Wainwright Bullish On Corbus Therapeutics' Cystic Fibrosis Opportunity Benzinga
Dec-20-18 06:47PM  Stocks - Dow's Dour December Continues Amid Turmoil in Washington Investing.com
12:15PM  5 Low-Priced Stocks Under $10 for the New Year InvestorPlace
10:13AM  The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte Zacks
Dec-19-18 12:04PM  Vertex Announces it will Submit Cystic Fibrosis Medicines ORKAMBI® (lumacaftor/ivacaftor) as well as SYMKEVI® (tezacaftor/ivacaftor) to be Used in Combination with ivacaftor, to the Scottish Medicines Consortium for Appraisal Business Wire
09:17AM  Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY Zacks
09:12AM  Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint Zacks
05:37AM  Waltham's Eloxx aims to reach cystic fibrosis patients that Vertex can't American City Business Journals
Dec-18-18 08:55AM  Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved Benzinga
08:30AM  Vertex Announces Positive Phase 2 Data in Third Proof-of-Concept Study with the NaV1.8 Inhibitor VX-150 Business Wire
07:17AM  3 Biotechs With Potential Blockbusters Near the Finish Line Motley Fool
Dec-17-18 07:00AM  Report finds growing pains for rare disease drugs, but local biotechs buck trend American City Business Journals
Dec-14-18 08:23AM  5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019 Zacks
Dec-13-18 08:00AM  Health Canada Grants Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease Business Wire
07:32AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Dec-10-18 08:41AM  Should Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Be Your Next Stock Pick? Simply Wall St.
07:58AM  5 Top Drug/Biotech Merger & Acquisition Targets for 2019 Zacks
Dec-09-18 11:50AM  Should You Avoid Vertex Pharmaceuticals Incorporated (VRTX)? Insider Monkey
Dec-07-18 02:24PM  3 Highest-Growth Stocks in Today's Market Motley Fool
Dec-05-18 09:10AM  Biotech Stock Roundup: ASH Meet in Focus, Gilead's Drugs Get Approval in China Zacks
Dec-03-18 04:18PM  Monday Madness: Ready to Add Some Stocks to Your Holiday Wishlist? TheStreet.com
11:17AM  Top Analysts: Five 'Strong Buy' Stocks for 2019 TheStreet.com
Dec-01-18 12:00PM  Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals Motley Fool
Nov-30-18 10:31AM  Why Crispr Therapeutics Stock Is Up By 65% So Far in 2018 Motley Fool
Nov-29-18 04:05PM  Moderna IPO On Path To Be Largest Offering Of Venture-Backed Biotech Investor's Business Daily
03:02AM  Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) to Treat Patients with Cystic Fibrosis Aged 12 to <24 months with Certain Mutations in the CFTR Gene Business Wire
Nov-28-18 03:21PM  Vertex Looks to Capture the Rest of Its Multibillion-Dollar Market Motley Fool
08:41AM  Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed Zacks
08:22AM  Biotech Stock Roundup: Pipeline Updates From CELG & VRTX, ZFGN Plunges on Hold News Zacks
07:00AM  Today's Research Reports on Trending Tickers: Vertex Pharmaceuticals and Tesaro ACCESSWIRE
Nov-27-18 06:58PM  Stocks - Dow Closes Higher as Larry Kudlow Fuels Trade Deal Hopes Investing.com
05:26PM  TopGainers - Vertex Pharmaceuticals, Delta, L Brands Climb as Markets Rebound Investing.com
04:10PM  Vertex Stock Pops As Triple Pill Shows Promise In Cystic Fibrosis Investor's Business Daily
03:07PM  Stock News Today: Verizon Leads Dow Jones; Vertex Soars On Drug Data Investor's Business Daily
01:10PM  Vertex posts positive data from cystic fibrosis triple combo trials Reuters
10:27AM  Vertex reports early success in triple combo cystic fibrosis drug trials American City Business Journals
08:00AM  Two Phase 3 Studies of the Triple Combination of VX-659, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis Business Wire
Nov-26-18 02:46PM  Mass. biotech leaders voice alarm over report of first gene-edited babies American City Business Journals
Nov-21-18 11:21AM  Biotech Stock Roundup: GILD's Drug Wins Nod in China, Arena Up On Licensing Deal Zacks
09:47AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Nov-19-18 03:51PM  Vertex (VRTX) Gets Positive CHMP Opinion for Orkambi in Kids Zacks
Nov-16-18 07:57AM  Vertex Receives European CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease Business Wire
Nov-14-18 07:25AM  Analysis: Positioning to Benefit within Vertex Pharmaceuticals, MISONIX, Whiting Petroleum, Kewaunee Scientific, Arotech, and Apollo Commercial Real Estate Finance Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-09-18 08:12AM  Celldex (CLDX) Q3 Earnings Beat Estimates, Revenues Miss Zacks
Nov-08-18 10:27AM  Perrigo (PRGO) Beats on Q3 Earnings, Cuts View, Shares Down Zacks
06:00AM  3 Biotech Stocks Poised for Big Rebounds Investopedia
Nov-07-18 07:46PM  Cambridge's Editas asks FDA to start gene editing trial American City Business Journals
Nov-02-18 11:31AM  VIVUS (VVUS) Q3 Loss Narrower Than Expected, Revenues Up Y/Y Zacks
09:15AM  Geron's (GERN) Q3 Earnings Beat, Revenues Miss, Shares Down Zacks
08:00AM  9 Blue Chip Giants That Will Crush the S&P 500 Investopedia
Nov-01-18 07:42AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals Zacks
04:00AM  Vertex Announces European Authorization for Third Cystic Fibrosis Medicine SYMKEVI® (tezacaftor/ivacaftor), to be used in combination with ivacaftor (KALYDECO®), for People with CF Aged 12 and Older with Certain Mutations in the CFTR gene Business Wire
Oct-31-18 02:08PM  Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal Zacks
Oct-30-18 09:48AM  Is a Beat in Store for CRISPR (CRSP) This Earnings Season? Zacks
Oct-29-18 09:12AM  Vertex Pharmaceuticals Waits to Hit the Triple Motley Fool
Oct-28-18 09:33AM  Better Buy: Vertex Pharmaceuticals Incorporated vs. Incyte Corporation Motley Fool
Oct-27-18 08:31AM  AbbVie Takes Aim at Vertex Pharmaceuticals Incorporated Motley Fool
Oct-26-18 08:15AM  Edited Transcript of VRTX earnings conference call or presentation 24-Oct-18 8:30pm GMT Thomson Reuters StreetEvents
Oct-25-18 12:31PM  Vertex (VRTX) Q3 Earnings and Revenues Surpass Estimates Zacks
08:00AM  Today's Research Reports on Trending Tickers: Vertex Pharmaceuticals and Celgene ACCESSWIRE
Oct-24-18 08:23PM  Vertex Pharmaceuticals Inc (VRTX) Q3 2018 Earnings Conference Call Transcript Motley Fool -6.36%
05:15PM  Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Surpass Estimates Zacks
04:10PM  Vertex: 3Q Earnings Snapshot Associated Press
04:01PM  Vertex Reports Third-Quarter 2018 Financial Results Business Wire
08:22AM  Vertex Pharmaceuticals Q3 Earnings Outlook Benzinga
Oct-23-18 09:31AM  Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT Zacks
Oct-22-18 01:56PM  5 Low-Priced Biotech Stocks to Take Advantage of the Market Rout InvestorPlace
12:08PM  Is a Beat in Store for Vertex (VRTX) This Earnings Season? Zacks
11:22AM  What's in Store for Anika Therapeutics (ANIK) in Q3 Earnings? Zacks
Oct-21-18 05:15PM  The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs Benzinga
06:33AM  Better Buy: CRISPR Therapeutics AG vs. Intellia Therapeutics Inc. Motley Fool
Oct-19-18 05:41PM  Why Proteostasis Therapeutics Tumbled 23.2% on Friday Motley Fool
01:02PM  UAB researchers leading way on drug regimen battling cystic fibrosis American City Business Journals
10:27AM  Why Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is A Financially Healthy Company Simply Wall St.
07:54AM  Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene Business Wire
Oct-18-18 01:34PM  Growth Stocks Smacked Again As Market Correction Intensifies Investor's Business Daily
11:45AM  Vertex Data Presented at North American Cystic Fibrosis Conference (NACFC) Demonstrate Rapid Progress Toward Expanding and Enhancing Options for Treating the Underlying Cause of Cystic Fibrosis Business Wire
Oct-17-18 10:31AM  Vertex Pharmaceuticals (VRTX) Q3 Earnings Preview: What's Shaping Up? Zacks
09:30AM  CELG vs. VRTX: Which Stock Should Value Investors Buy Now? Zacks
Oct-16-18 04:01PM  Vertex to Announce Third Quarter 2018 Financial Results on October 24 Business Wire
Oct-12-18 02:23PM  3 High-Reward Stocks From 3 Emerging Trends InvestorPlace
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for the treatment of pain; CTX001, an investigational gene editing treatment that is in Phase I/II trial for the treatment of beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc; and Q-State Biosciences, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Parini MichaelEVP, CL&AOJan 14Option Exercise90.292,125191,86641,734Jan 15 04:03 PM
Parini MichaelEVP, CL&AOJan 14Sale186.712,125396,75939,609Jan 15 04:03 PM
Parini MichaelEVP, CL&AOJan 04Option Exercise122.454,250520,41343,859Jan 07 04:02 PM
Parini MichaelEVP, CL&AOJan 04Sale165.904,250705,07539,609Jan 07 04:02 PM
SACHS BRUCE IDirectorDec 06Option Exercise34.2410,000342,40023,011Dec 07 04:06 PM
Silva Paul MSVP & Corp ControllerDec 03Option Exercise86.5280969,99516,896Dec 04 04:04 PM
Silva Paul MSVP & Corp ControllerDec 03Sale186.52809150,89516,087Dec 04 04:04 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 15Sale163.7510016,37539,113Nov 19 05:23 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 15Sale163.75294,74946,752Nov 19 05:28 PM
Sachdev AmitEVP, CRONov 15Sale163.75619,98946,662Nov 19 05:34 PM
Parini MichaelEVP, CL&AONov 15Sale163.759014,73839,609Nov 19 05:47 PM
Silva Paul MSVP & Corp ControllerNov 15Sale163.75121,96516,087Nov 19 05:52 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 07Option Exercise131.892,125280,26641,238Nov 08 04:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 07Option Exercise131.892,125280,26648,877Nov 08 04:26 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 07Sale181.892,125386,51639,113Nov 08 04:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 07Sale179.002,125380,37546,752Nov 08 04:26 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 05Option Exercise86.522,330201,59241,443Nov 06 04:11 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 05Option Exercise103.095,803598,21151,002Nov 06 04:24 PM
Parini MichaelEVP, CL&AONov 05Option Exercise86.522,330201,59241,939Nov 06 04:32 PM
Sachdev AmitEVP, CRONov 05Option Exercise86.521,941167,93548,603Nov 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 05Sale172.082,330400,94639,113Nov 06 04:11 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 05Sale172.085,803998,58046,752Nov 06 04:24 PM
Parini MichaelEVP, CL&AONov 05Sale172.082,330400,94639,609Nov 06 04:32 PM
Sachdev AmitEVP, CRONov 05Sale173.731,941337,20446,662Nov 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 02Option Exercise91.051,796163,52640,909Nov 06 04:11 PM
Sachdev AmitEVP, CRONov 02Option Exercise91.052,155196,21348,817Nov 06 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 02Option Exercise91.052,155196,21348,907Nov 05 04:52 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 02Sale175.361,796314,94739,113Nov 06 04:11 PM
Sachdev AmitEVP, CRONov 02Sale172.862,155372,50546,662Nov 06 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 02Sale175.362,155377,90146,752Nov 05 04:52 PM
Parini MichaelEVP, CL&AOOct 12Option Exercise90.292,125191,86641,734Oct 16 04:29 PM
Parini MichaelEVP, CL&AOOct 12Sale177.202,125376,55039,609Oct 16 04:29 PM
Kewalramani ReshmaEVP and CMOOct 08Sale186.952,305430,9201,909Oct 09 04:50 PM
Parini MichaelEVP, CL&AOOct 04Option Exercise122.454,250520,41343,859Oct 05 05:35 PM
Parini MichaelEVP, CL&AOOct 04Sale191.584,250814,21539,609Oct 05 05:35 PM
Bhatia Sangeeta N.DirectorOct 03Option Exercise126.386,818861,6509,579Oct 05 05:28 PM
Bhatia Sangeeta N.DirectorOct 03Sale192.136,8181,309,9424,879Oct 05 05:28 PM
ALTSHULER DAVIDEVP, Global Research and CSOOct 01Option Exercise155.572,445380,36941,558Oct 02 04:30 PM
Graney ThomasChief Financial OfficerOct 01Sale193.241,076207,92612,430Oct 02 04:24 PM
ALTSHULER DAVIDEVP, Global Research and CSOOct 01Sale194.622,445475,84639,113Oct 02 04:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 28Option Exercise131.892,125280,26641,238Aug 30 04:07 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 28Sale181.892,125386,51639,113Aug 30 04:07 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 03Option Exercise103.095,803598,21152,555Aug 06 05:21 PM
Silva Paul MSVP & Corp ControllerAug 03Option Exercise86.5280969,99516,896Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 03Option Exercise86.522,330201,59241,443Aug 06 05:42 PM
Sachdev AmitEVP, CROAug 03Option Exercise86.521,942168,02248,604Aug 06 06:19 PM
Parini MichaelEVP, CL&AOAug 03Option Exercise86.522,330201,59241,939Aug 07 04:46 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 03Sale174.205,8031,010,88346,752Aug 06 05:21 PM
Silva Paul MSVP & Corp ControllerAug 03Sale174.20809140,92816,087Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 03Sale174.202,330405,88639,113Aug 06 05:42 PM
Sachdev AmitEVP, CROAug 03Sale175.101,942340,05046,662Aug 06 06:19 PM
Parini MichaelEVP, CL&AOAug 03Sale174.202,330405,88639,609Aug 07 04:46 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Option Exercise111.334,280476,47948,907Aug 06 05:21 PM
Silva Paul MSVP & Corp ControllerAug 02Option Exercise91.051,289117,36317,376Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 02Option Exercise91.051,796163,52640,909Aug 06 05:42 PM
Sachdev AmitEVP, CROAug 02Option Exercise91.052,155196,21348,817Aug 06 06:19 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Sale176.784,280756,61646,752Aug 06 05:21 PM
Silva Paul MSVP & Corp ControllerAug 02Sale174.591,289225,04716,087Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 02Sale174.591,796313,56439,113Aug 06 05:42 PM
Sachdev AmitEVP, CROAug 02Sale176.732,155380,85246,662Aug 06 06:19 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 16Option Exercise96.872,125205,84948,877Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 16Option Exercise96.871,719166,52048,381Jul 17 06:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOJul 16Option Exercise131.8923,3753,082,92962,488Jul 18 05:32 PM
Silva Paul MSVP & Corp ControllerJul 16Option Exercise96.8786083,30816,947Jul 18 05:44 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 16Sale179.852,125382,18146,752Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 16Sale180.361,719310,04246,662Jul 17 06:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOJul 16Sale182.0023,3754,254,25039,113Jul 18 05:32 PM
Silva Paul MSVP & Corp ControllerJul 16Sale179.85860154,67116,087Jul 18 05:44 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 13Option Exercise131.896,375840,79953,127Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 13Option Exercise96.8712,0311,165,44358,693Jul 17 06:30 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 13Sale179.006,3751,141,12546,752Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 13Sale180.0012,0312,165,58046,662Jul 17 06:30 PM
Silva Paul MSVP & Corp ControllerJul 12Option Exercise90.2986077,64916,947Jul 16 04:19 PM
Parini MichaelEVP, CL&AOJul 12Option Exercise90.292,125191,86641,734Jul 16 04:37 PM
Silva Paul MSVP & Corp ControllerJul 12Sale175.02860150,51716,087Jul 16 04:19 PM
Parini MichaelEVP, CL&AOJul 12Sale175.022,125371,91839,609Jul 16 04:37 PM
Parini MichaelEVP, CL&AOJul 05Option Exercise122.454,250520,41343,859Jul 09 06:14 PM
Parini MichaelEVP, CL&AOJul 05Sale168.384,250715,61539,609Jul 09 06:14 PM
Sachdev AmitEVP, CROJun 29Option Exercise88.904,096364,14850,758Jul 03 04:12 PM
Silva Paul MSVP & Corp ControllerJun 29Option Exercise91.502,957270,56917,376Jul 03 04:16 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 29Option Exercise89.153,708330,57850,460Jul 03 04:20 PM
SMITH IAN FEVP, COOJun 29Option Exercise131.8923,3753,082,92970,074Jul 03 04:25 PM
ALTSHULER DAVIDEVP, Global Research and CSOJun 29Option Exercise87.1313,4451,171,39783,444Jul 03 04:29 PM
SMITH IAN FEVP, COOJun 29Sale166.3023,3753,887,17346,699Jul 03 04:25 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 29Sale169.003,708626,65246,752Jul 03 04:20 PM
Silva Paul MSVP & Corp ControllerJun 29Sale166.522,957492,38516,087Jul 03 04:16 PM
Sachdev AmitEVP, CROJun 29Sale167.634,096686,61546,662Jul 03 04:12 PM
ALTSHULER DAVIDEVP, Global Research and CSOJun 29Sale164.9844,3317,313,59639,113Jul 03 04:29 PM
LEIDEN JEFFREY MCEO & PresidentJun 22Option Exercise83.36106,5008,877,840297,260Jun 26 05:18 PM
SMITH IAN FEVP, COOJun 22Option Exercise109.144,250463,84550,949Jun 26 05:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 22Option Exercise109.144,250463,84551,002Jun 26 05:20 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJun 22Sale159.004,250675,75046,752Jun 26 05:20 PM
SMITH IAN FEVP, COOJun 22Sale160.004,250680,00046,699Jun 26 05:18 PM
LEIDEN JEFFREY MCEO & PresidentJun 22Sale160.00140,21122,433,760157,049Jun 26 05:18 PM
Bhatia Sangeeta N.DirectorJun 04Sale152.05875133,0444,879Jun 05 05:39 PM
Silva Paul MSVP & Corp ControllerMay 15Sale155.7820131,31216,087May 16 05:27 PM
Parini MichaelEVP, CL&AOMay 15Sale155.788513,24139,609May 16 05:24 PM
SMITH IAN FEVP, COOMay 15Sale155.7821733,80446,699May 16 05:21 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerMay 15Sale155.7813821,49846,752May 16 05:11 PM
Sachdev AmitEVP, CROMay 15Sale155.788312,93046,662May 16 05:06 PM